Altree-Tacha David, Tyrrell Jillian, Haas Thomas
From Chief Scientific Officer (Dr Altree-Tacha) and the Department of Research and Development (Dr Tyrrell), Biocare Medical, Concord, California; and the Department of Pathology, Mercy Health System, Janesville, Wisconsin (Dr Haas).
Arch Pathol Lab Med. 2017 Jan;141(1):144-150. doi: 10.5858/arpa.2015-0404-OA.
-CDH17, which is expressed in the intestinal epithelium, is a novel oncogene involved in tumor invasion and metastasis. A panel consisting of cytokeratin (CK) 7, CD20, and CDX2 antibodies is typically used to diagnose gastrointestinal adenocarcinomas. However, studies have shown that CDH17 is a highly specific marker for gastrointestinal adenocarcinoma and may be important in clinical diagnosis.
-To evaluate the sensitivity and specificity of CDH17, CK20, and CDX2 antibodies in neoplastic tissues, with emphasis on colon, stomach, and esophageal gastrointestinal lineage.
-Immunohistochemistry was performed with CDH17, CK20, and CDX2 antibodies on formalin-fixed, paraffin-embedded tissue microarrays from normal (n = 26) and neoplastic (n = 884) tissues.
-CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. In metastatic colon cancers, CDH17, CK20, and CDX2 positive staining was observed in 90.6% (29 of 32), 59.4% (19 of 32), and 81.3% (26 of 32) of cases, respectively. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. In esophageal adenocarcinomas, CDH17, CK20, and CDX2 stained 38.7% (12 of 31), 25.8% (8 of 31), and 29% (9 of 31) of specimens, respectively. Low or no expression was observed in other neoplastic tissues, except pancreatic cancers, where CDH17 displayed higher expression than CK20 and CDX2.
-CDH17 is a specific and more sensitive marker in the gastrointestinal tract than CK20 and CDX2. CDH17 may be especially valuable when gastrointestinal tumors are suspected in cancers of unknown primary.
-CDH17在肠上皮中表达，是一种参与肿瘤侵袭和转移的新型癌基因。通常使用由细胞角蛋白（CK）7、CD20和CDX2抗体组成的一组抗体来诊断胃肠道腺癌。然而，研究表明CDH17是胃肠道腺癌的高度特异性标志物，可能在临床诊断中具有重要意义。
-评估CDH17、CK20和CDX2抗体在肿瘤组织中的敏感性和特异性，重点关注结肠、胃和食管的胃肠道谱系。
-使用CDH17、CK20和CDX2抗体对来自正常（n = 26）和肿瘤（n = 884）组织的福尔马林固定、石蜡包埋组织微阵列进行免疫组织化学检测。
-CDH17免疫染色在97.3%（149例中的145例）的结肠腺癌中呈阳性，而CK20和CDX2分别在88.6%（149例中的132例）和93.3%（149例中的139例）中呈阳性染色。在转移性结肠癌中，分别在90.6%（32例中的29例）、59.4%（32例中的19例）和81.3%（32例中的26例）的病例中观察到CDH17、CK20和CDX2阳性染色。在胃腺癌中，64.0%（175例中的112例）的组织CDH17染色呈阳性，而CK20和CDX2分别仅在24.6%（175例中的43例）和46.9%（175例中的82例）中观察到染色。在食管腺癌中，CDH17、CK20和CDX2分别在38.7%（31例中的12例）、25.8%（31例中的8例）和29%（31例中的9例）的标本中染色。在其他肿瘤组织中观察到低表达或无表达，除了胰腺癌，其中CDH17的表达高于CK20和CDX2。
-CDH17在胃肠道中是比CK20和CDX2更特异、更敏感的标志物。当在原发灶不明的癌症中怀疑有胃肠道肿瘤时，CDH17可能特别有价值。
